Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on MDXG stock, giving a Buy rating on February 27.
Anthony Petrone has given his Buy rating due to a combination of factors including MiMedx Group’s strong product sales performance, which surpassed market expectations. Despite challenges such as competitor reimbursement dynamics and sales force turnover, the company demonstrated resilience by achieving growth against tough prior-year comparisons, indicating effective execution.
Moreover, Petrone anticipates that the upcoming finalization of the Local Coverage Determination (LCD) will benefit MiMedx, as the company holds a significant position in the regulated Skin Substitute market. With the potential for substantial market share gains in Medicare Skin Substitute payments and the expectation of clarity in the second half of 2025, Petrone sees MiMedx as well-positioned to capture additional market opportunities, supporting his Buy recommendation.
In another report released on February 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13.00 price target.